Search Results - "Gall, John Le"

The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity by Gautam, Sanjivan, Fioravanti, Jessica, Zhu, Wei, Le Gall, John B., Brohawn, Philip, Lacey, Neal E., Hu, Jinhui, Hocker, James D., Hawk, Nga Voong, Kapoor, Veena, Telford, William G., Gurusamy, Devikala, Yu, Zhiya, Bhandoola, Avinash, Xue, Hai-Hui, Roychoudhuri, Rahul, Higgs, Brandon W., Restifo, Nicholas P., Bender, Timothy P., Ji, Yun, Gattinoni, Luca

“…Stem cells are maintained by transcriptional programs that promote self-renewal and repress differentiation. Here, we found that the transcription factor c-Myb…”
Get full text

miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate by Ji, Yun, Fioravanti, Jessica, Zhu, Wei, Wang, Hongjun, Wu, Tuoqi, Hu, Jinhui, Lacey, Neal E., Gautam, Sanjivan, Le Gall, John B., Yang, Xia, Hocker, James D., Escobar, Thelma M., He, Shan, Dell’Orso, Stefania, Hawk, Nga V., Kapoor, Veena, Telford, William G., Di Croce, Luciano, Muljo, Stefan A., Zhang, Yi, Sartorelli, Vittorio, Gattinoni, Luca

“…T cell senescence and exhaustion are major barriers to successful cancer immunotherapy. Here we show that miR-155 increases CD8 + T cell antitumor function by…”
Get full text

Test Dose Pharmacokinetics in Pediatric Patients Receiving Once‐Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? by Brooks, Kristina M., Jarosinski, Paul, Hughes, Thomas, Kang, Elizabeth, Shah, Nirali N., Gall, John B. Le, Hickstein, Dennis D., Ravin, Suk See, George, Jomy M., Kumar, Parag

“…Intravenous (IV) busulfan test dose pharmacokinetics (PK) has been shown to accurately predict once‐daily dose requirements and improve outcomes in adult…”
Get full text

544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma by Gastman, Brian, Hamid, Omid, Corrie, Pippa, Gibney, Geoffrey, Daniels, Gregory, Chmielowski, Bartosz, Thomas, Sajeve, Domingo-Musibay, Evidio, Lawrence, Donald, Jiang, Yizhou, Kennedy, Audrey, Aycock, Jeff, Alvarez-Rodriguez, Ruben, Robbins, Paul, Gall, John Le, Roberts, Zachary, Hawkins, Robert, Sarnaik, Amod

“…BackgroundPatients with advanced cutaneous melanoma and persistent disease after checkpoint inhibitor therapy have poor outcomes and limited treatment options,…”
Get full text

A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma by Cornell, Robert F, Bishop, Michael R, Kumar, Shaji, Giralt, Sergio A, Nooka, Ajay K, Larson, Sarah M, Locke, Frederick L, Raje, Noopur S, Lei, Lei, Dong, Jinghui, Le Gall, John B, Rossi, John M, Orlowski, Robert Z

“…Despite advances in treatment, most patients with multiple myeloma (MM) will relapse, and long-term survival remains poor. B-cell maturation antigen (BCMA) is…”
Get full text

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL) by Kenderian, Saad S., Oluwole, Olalekan O., McCarthy, Philip L., Reshef, Ran, Shiraz, Parveen, Ahmed, Omar, Le Gall, John, Nahas, Myrna, Tang, Lily, Neelapu, Sattva S.

“…Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for pts with R/R LBCL with ≥ 2 prior systemic therapies…”
Get full text

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas by Locke, Frederick L., Munoz, Javier L., Tees, Michael T., Lekakis, Lazaros J., Eradat, Herbert A., de Vos, Sven, Nath, Rajneesh, Stevens, Don A., Malik, Shahbaz A., Shouse, Geoffrey P., Hamadani, Mehdi, Oluwole, Olalekan O., Perales, Miguel-Angel, Miklos, David B., Nguyen, Anh, Feng, Amy, Navale, Lynn, Murray, Elaine, Kaufman, Greg P., Kai, Kazuharu, Le Gall, John B., Neelapu, Sattva S.

“…Background: While breakthroughs in hematologic malignancies with autologous CAR T-cell therapies have been met with growing clinical interest due to impressive…”
Get full text

The transcription factor c-Myb regulates CD8.sup.+ T cell stemness and antitumor immunity by Gautam, Sanjivan, Fioravanti, Jessica, Zhu, Wei, Le Gall, John B, Brohawn, Philip, Lacey, Neal E, Hu, Jinhui

“…Stem cells are maintained by transcriptional programs that promote self-renewal and repress differentiation. Here, we found that the transcription factor c-Myb…”
Get full text

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma by Gastman, Brian, Hamid, Omid, Corrie, Philippa Gail, Chmielowski, Bartosz, Thomas, Sajeve Samuel, Daniels, Gregory A., Domingo-Musibay, Evidio, Lawrence, Donald P., Whitman, Eric D., Gibney, Geoffrey Thomas, Olszanski, Anthony J., Jiang, Yizhou, Kennedy, Audrey, Aycock, Jeff, Robbins, Paul B., Le Gall, John Brian, Roberts, Zachary, Hawkins, Robert E., Sarnaik, Amod

“…TPS9594 Background: Patients (pts) with advanced (unresectable or metastatic) cutaneous melanoma and persistent disease after checkpoint inhibitor therapy have…”
Get full text

CT-419 ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) by Miklos, David, Bharadwaj, Sushma, Holmes, Houston, Oluwole, Olalekan, Jallouk, Andrew, Neelapu, Sattva, Jain, Nitin, Nath, Rajneesh, Munoz, Javier, Bryan, Locke, De Vos, Sven, Eradat, Herbert, Patel, Rushang, Tees, Michael, Tsai, Stephanie, Cahill, Kirk, Sohl, Melhem, Shouse, Geoffrey, Stevens, Don, Fisher, Paul, Feng, Amy, Severyn, Christopher, Le Gall, John, Locke, Frederick, Munoz, Javier

“…Bruton tyrosine kinase inhibitors (BTKi) and B-cell lymphoma 2 inhibitors (BCL2i) have improved outcomes in CLL/SLL, but double refractoriness confers poor…”
Get full text

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy by Westin, Jason, Burke, John, Lynch, Ryan, Abramson, Jeremy, Stevens, Don, Matasar, Matthew, Fitzgerald, Lindsey, Zausner Skarbnik, Alan, Iragavarapu, Chaitanya, Essell, James, Hunter, Bradley, Merchant, Akil, Varadarajan, Indumathy, Tandra, Anand, Licitra, Edward, Bryan, Locke, Patel, Rushang D., Behl, Rajesh, Sharmann, Jeff, Holmes, Houston E., Fanning, Suzanne, Yimer, Habte, Gandhi, Mitul, Simmons, Gary, Feng, Amy, Navale, Lynn, Ghatta, Srinivas, Le Gall, John B., Herrera, Alex F.

Get full text

CT-412 ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy by Westin, Jason, Burke, John, Lynch, Ryan, Abramson, Jeremy, Stevens, Don, Matasar, Matthew, Fitzgerald, Lindsey, Zausner Skarbnik, Alan, Iragavarapu, Chaitanya, Essell, James, Hunter, Bradley, Merchant, Akil, Varadarajan, Indumathy, Rotte, Anand, Licitra, Edward, Bryan, Locke, Patel, Rushang D., Behl, Rajesh, Sharmann, Jeff, Holmes, Houston E., Fanning, Suzanne, Yimer, Habte, Gandhi, Mitul, Simmons, Gary, Feng, Amy, Navale, Lynn, Ghatta, Srinivas, Le Gall, John B., Herrera, Alex F.

“…First-line therapy outcomes for patients with LBCL are favorable with R-CHOP (~60% cure rate; Spinner, Oncology 2022). However, ~30% who complete 1L treatment,…”
Get full text

ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) by Miklos, David, Bharadwaj, Sushma, Holmes, Houston, Oluwole, Olalekan, Jallouk, Andrew, Neelapu, Sattva, Jain, Nitin, Nath, Rajneesh, Munoz, Javier, Bryan, Locke, De Vos, Sven, Eradat, Herbert, Patel, Rushang, Tees, Michael, Tsai, Stephanie, Cahill, Kirk, Sohl, Melhem, Shouse, Geoffrey, Stevens, Don, Fisher, Paul, Feng, Amy, Severyn, Christopher, Le Gall, John, Locke, Frederick, Pinilla, Javier

Get full text

781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors by Yeku, Oladapo, Olson, Daniel, Ward, Jeffrey, Patel, Sandip, Aycock, Jeff, Donahue, Amber, Jiang, Yizhou, John Le Gall, Roberts, Zachary, Alvarez-Rodríguez, Rubén, Seng, Judy, Shen, Tong, Kothari, Nishi

“…BackgroundDespite the benefits of immune checkpoint inhibitors (ICIs) in solid tumors, additional treatment options are needed for patients with primary or…”
Get full text

A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen by Satwani, Prakash, Bhatia, Monica, Garvin, James H, George, Diane, Dela Cruz, Filemon, Le Gall, John, Jin, Zhezhen, Schwartz, Joseph, Duffy, Deirdre, van de Ven, Carmella, Foley, Sandra, Hawks, Ria, Morris, Erin, Baxter-Lowe, Lee Ann, Cairo, Mitchell S

“…Children with high-risk acute myelogenous leukemia (AML) (induction failure [IF], refractory relapse [RR], third complete remission [CR3]) have dismal…”
Get full text